Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAMSA-BU versus standard reduced-intensity conditioning before allogeneic stem cell transplantation in AML and MDS
ISRCTN50855000Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Oct 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of fludarabine, cytarabine, amsacrine, busulfan, melphalan and 2 more in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by University of Birmingham. Primary endpoint: Overall survival. Started Oct 2013; status: completed.
02
Drugs
fludarabinecytarabineamsacrinebusulfanmelphalan
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ISRCTN50855000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN50855000.